Pay in 4 interest-free payments of $5.59 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
Clinical Trial Evidence & Failure The definitive human evidence for AOD-9604 comes from a Phase 2b double-blind, placebo-controlled trial published by Stier et al
Peptides expected to return to legal compounding status include: BPC-157 - studied for tissue repair, gut healing, and inflammation reduction Thymosin Alpha-1 - an immune-modulating peptide used in infectious disease and oncology support TB-500 (Thymosin Beta-4) - studied for muscle repair, flexibility, and recovery CJC-1295 and Ipamorelin - growth hormone-releasing peptides supporting sleep, metabolism, and lean muscle AOD-9604 - a peptide fragment studied for fat metabolism Selank and Semax - neuropeptides studied for cognitive function and anxiety GHK-Cu - a copper peptide studied for wound healing and regeneration MOTS-C - a mitochondrial peptide studied for metabolic regulation Important: Category 1 reclassification is not the same as FDA approval
Double check if you are using the correct needle size and injection technique
Because of its interaction with NNMT-related pathways, the compound has been used in experimental models studying metabolic signalling networks, enzyme inhibition dynamics and cellular regulatory processes
US$ 25.44
US$ 26.59
US$ 24.95
US$ 22.87
US$ 28.98
